Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
International Journal for Equity in Health
Published in: International Journal for Equity in Health 1/2011

Open Access 01-12-2011 | Commentary

Global challenges of implementing human papillomavirus vaccines

Authors: Janice E Graham, Amrita Mishra

Published in: International Journal for Equity in Health | Issue 1/2011

Login to get access

Abstract

Human Papillomavirus vaccines are widely hailed as a sweeping pharmaceutical innovation for the universal benefit of all women. The implementation of the vaccines, however, is far from universal or equitable. Socio-economically marginalized women in emerging and developing, and many advanced economies alike, suffer a disproportionately large burden of cervical cancer. Despite the marketing of Human Papillomavirus vaccines as the solution to cervical cancer, the market authorization (licensing) of the vaccines has not translated into universal equitable access. Vaccine implementation for vulnerable girls and women faces multiple barriers that include high vaccine costs, inadequate delivery infrastructure, and lack of community engagement to generate awareness about cervical cancer and early screening tools. For Human Papillomavirus vaccines to work as a public health solution, the quality-assured delivery of cheaper vaccines must be integrated with strengthened capacity for community-based health education and screening.
Appendix
Available only for authorised users
Literature
1.
Koulova A, Tsui J, Irwin K, Van Damme P, Biellik R, Aguado MT: Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine. 2008, 26: 6529-41. 10.1016/j.vaccine.2008.08.067.PubMed
2.
3.
Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP): Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007, 56 (RR-2): 1-24.PubMed
4.
Foerster V, Murtagh J: Human papillomavirus (HPV) vaccines: a Canadian update. Issues Emerg Health Technol. 2007, 109: 1-8.PubMed
5.
Monie A, Hung CF, Roden R, Wu TC: Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics. 2008, 2: 97-105.PubMed
6.
Centers for Disease Control and Prevention (CDC): FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the advisory committee on immunization practices (ACIP). Morbidity and Mortality Weekly Report (MMWR). 2010, 59: 626-629.
7.
Centers for Disease Control and Prevention (CDC): FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report (MMWR). 2010, 59: 630-2.
8.
Schiller JT, Castellsagué X, Villa LL, Hildesheim A: An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 2008, 26 (Suppl 10): K53-61.PubMedCentralPubMed
9.
Fisher R, Darrow DH, Tranter M, Williams JV: Human papillomavirus vaccine: recommendations, issues and controversies. Curr Opin Pediatr. 2008, 20: 441-5. 10.1097/MOP.0b013e328305e298.PubMed
10.
Garland SM, Smith JS: Human papillomavirus vaccines: current status and future prospects. Drugs. 2010, 70: 1079-98. 10.2165/10898580-000000000-00000.PubMed
11.
Frazer IH: Measuring serum antibody to human papillomavirus following infection or vaccination. Gynecol Oncol. 2010, 118 (Suppl 1): S8-11.PubMed
12.
FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R: Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010, 341: c3493-
13.
Harper DM: Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health. Public Health Genomics. 2009, 12: 319-30. 10.1159/000214922.PubMed
14.
Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M: Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer. 2008, 113 (Suppl 7): 1980-93.PubMed
15.
Wright TC, Van Damme P, Schmitt HJ, Meheus A: Chapter 14: HPV vaccine introduction in industrialized countries. Vaccine. 2006, 24 (Suppl 3): 122-31.
16.
Lévy-Bruhl D, Bousquet V, King LA, O'Flanagan D, Bacci S, Lopalco PL, Salmaso S, country specific VENICE gate keepers and contact points: The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 survey. Eur J Cancer. 2009, 45: 2709-13. 10.1016/j.ejca.2009.07.023.PubMed
17.
18.
Agosti JM, Goldie SJ: Introducing HPV vaccine in developing countries--key challenges and issues. N Engl J Med. 2007, 356: 1908-10. 10.1056/NEJMp078053.PubMed
19.
Maybarduk P, Rimmington S: Compulsory Licenses: A Tool to Improve Global Access to the HPV Vaccine?. Am J Law Med. 2009, 35: 323-350.PubMed
20.
Andrus JK, Sherris J, Fitzsimmons JW, Kane MA, Aguado MT: Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement. Vaccine. 2008, 26 (Suppl 10): K87-92.PubMed
21.
Padmanabhan S, Amin T, Sampat B, Cook-Deegan R, Chandrasekharan S: Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India. Nat Biotechnol. 2010, 28: 671-8. 10.1038/nbt0710-671.PubMedCentralPubMed
22.
Graham J, Jones M: Rendre evident: une approche symetrique de la réglementation des produits thérapeutiques. (Determining evidence: a symmetrical approach to the regulation of therapeutic products.). Sociologie et sociétés. 2010, 42: 153-180.
23.
Erickson LJ, De Wals P, Farand L: An analytical framework for immunization programs in Canada. Vaccine. 2005, 23: 2470-6. 10.1016/j.vaccine.2004.10.029.PubMed
24.
Boutayeb A, Boutayeb S: The burden of non communicable diseases in developing countries. Int J Equity Health. 2005, 4: 2-10.1186/1475-9276-4-2.PubMedCentralPubMed
25.
Tsu VD: Overcoming barriers and ensuring access to HPV vaccines in low-income countries. Am J Law Med. 2009, 35: 401-13.PubMed
26.
27.
Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004, 111: 278-85. 10.1002/ijc.20244.PubMed
28.
Franco EL, Harper DM: Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine. 2005, 23: 2388-94. 10.1016/j.vaccine.2005.01.016.PubMed
29.
Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, Edmunds WJ, Claeys P, Goldenthal KL, Harper DM, Markowitz L: Human papillomavirus and HPV vaccines: a review. Bull World Health Organ. 2007, 85: 719-26. 10.2471/BLT.06.038414.PubMedCentralPubMed
30.
Galani E, Christodoulou C: Human papilloma viruses and cancer in the post-vaccine era. Clin Microbiol Infect. 2009, 15: 977-81. 10.1111/j.1469-0691.2009.03032.x.PubMed
31.
Stanley M: Potential mechanisms for HPV vaccine-induced long-term protection. Gynecol Oncol. 2010, 118 (1 Suppl): S2-7.PubMed
32.
Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S: A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet. 2005, 89 (Suppl 2): S4-S12.PubMed
33.
34.
Jones BA, Davey DD: Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med. 2000, 124: 672-81.PubMed
35.
Sankaranarayanan R, Bhatla N, Gravitt PE, Basu P, Esmy PO, Ashrafunnessa KS, Ariyaratne Y, Shah A, Nene BM: Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine. 2008, 26 (Suppl 12): M43-52.PubMed
36.
Othman NH, Rebolj M: Challenges to cervical screening in a developing country: The case of Malaysia. Asian Pac J Cancer Prev. 2009, 10: 747-52.PubMed
37.
Tay SK, Ngan HY, Chu TY, Cheung AN, Tay EH: Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan. Vaccine. 2008, 26 (Suppl 12): M60-70.PubMed
38.
Scarinci IC, Garcia FA, Kobetz E, Partridge EE, Brandt HM, Bell MC, Dignan M, Ma GX, Daye JL, Castle PE: Cervical cancer prevention: new tools and old barriers. Cancer. 2010, 116: 2531-42.PubMedCentralPubMed
39.
Manderson L, Hoban E: Cervical cancer services for Indigenous women: advocacy, community-based research and policy change in Australia. Women Health. 2006, 43: 69-88. 10.1300/J013v43n04_05.PubMed
40.
Elkan R, Avis M, Cox K, Wilson E, Patel S, Miller S, Deepak N, Edwards C, Staniszewska S, Kai J: The reported views and experiences of cancer service users from minority ethnic groups: a critical review of the literature. Eur J Cancer Care. 2007, 16: 109-21. 10.1111/j.1365-2354.2006.00726.x.
41.
McDonald JT, Kennedy S: Cervical cancer screening by immigrant and minority women in Canada. J Immigr Minor Health. 2007, 9: 323-34. 10.1007/s10903-007-9046-x.PubMed
42.
Johnson CE, Mues KE, Mayne SL, Kiblawi AN: Cervical cancer screening among immigrants and ethnic minorities: a systematic review using the Health Belief Model. J Low Genit Tract Dis. 2008, 12: 232-41. 10.1097/LGT.0b013e31815d8d88.PubMed
43.
Amankwah E, Ngwakongnwi E, Quan H: Why many visible minority women in Canada do not participate in cervical cancer screening. Ethn Health. 2009, 14: 337-49. 10.1080/13557850802699122.PubMed
44.
Ma GX, Toubbeh JI, Wang MQ, Shive SE, Cooper L, Pham A: Factors associated with cervical cancer screening compliance and noncompliance among Chinese, Korean, Vietnamese, and Cambodian women. J Natl Med Assoc. 2009, 101: 541-51.PubMed
45.
Samuel PS, Pringle JP, James NW, Fielding SJ, Fairfield KM: Breast, cervical, and colorectal cancer screening rates amongst female Cambodian, Somali, and Vietnamese immigrants in the USA. Int J Equity Health. 2009, 8: 30-10.1186/1475-9276-8-30.PubMedCentralPubMed
46.
ACOG Committee on Practice Bulletins--Gynecology: ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol. 2009, 114: 1409-20.
47.
Clarke AE, Casper M: From simple technology to complex arena: classification of Pap smears, 1917-90. Med Anthropol Q. 1996, 10: 601-23. 10.1525/maq.1996.10.4.02a00120.PubMed
48.
National Cancer Institute Workshop: The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. JAMA. 1989, 262: 931-4.
49.
Report of the 1991 Bethesda workshop: The revised Bethesda System for reporting cervical/vaginal cytologic diagnoses. Acta Cytol. 1992, 36: 273-6.
50.
McLachlin CM, Mai V, Murphy J, Fung-Kee-Fung M, Chambers A, Oliver TK: Ontario cervical cancer screening clinical practice guidelines. J Obstet Gynaecol Can. 2007, 29: 344-53.PubMed
51.
Sawaya GF: Cervical-cancer screening-new guidelines and the balance between benefits and harms. N Engl J Med. 2009, 361: 2503-5. 10.1056/NEJMp0911380.PubMed
52.
53.
Kitchener HC, Castle PE, Cox JT: Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine. 2006, 24: 63-70.
54.
Franco EL, Coutlée F, Ferenczy A: Integrating human papillomavirus vaccination in cervical cancer control programmes. Public Health Genomics. 2009, 12: 352-61. 10.1159/000214925.PubMed
55.
Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, Sellors JW, Franceschi S, Qiao YL, Castle PE, on behalf of Cervical Cancer Screening Group in China: Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 2010,
56.
Sankaranarayanan R, Basu P, Wesley RS, Mahe C, Keita N, Mbalawa CC, Sharma R, Dolo A, Shastri SS, Nacoulma M, Nayama M, Somanathan T, Lucas E, Muwonge R, Frappart L, Parkin DM: Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa. Int J Cancer. 2004, 110: 907-13. 10.1002/ijc.20190.PubMed
57.
Chirenje ZM, Rusakaniko S, Kirumbi L, Ngwalle EW, Makuta-Tlebere P, Kaggwa S, Mpanju-Shumbusho W, Makoae L: Situation analysis for cervical cancer diagnosis and treatment in east, central and southern African countries. Bull World Health Organ. 2001, 79: 127-32. 18PubMedCentralPubMed
58.
Boutayeb A: Developing countries and neglected diseases: challenges and perspectives. Int J Equity Health. 2007, 6: 20-10.1186/1475-9276-6-20.PubMedCentralPubMed
59.
Anorlu RI: Cervical cancer: the sub-Saharan African perspective. Reprod Health Matters. 2008, 16: 41-9. 10.1016/S0968-8080(08)32415-X.PubMed
60.
Hanna TP, Kangolle AC: Cancer control in developing countries: using health data and health services research to measure and improve access, quality and efficiency. BMC Int Health Hum Rights. 2010, 10: 24-10.1186/1472-698X-10-24.PubMedCentralPubMed
61.
Sankaranarayanan R, Thara S, Esmy PO, Basu P: Cervical cancer: screening and therapeutic perspectives. Med Princ Pract. 2008, 17: 351-64. 10.1159/000141498.PubMed
62.
Casper MJ, Carpenter LM: Sex, drugs, and politics: the HPV vaccine for cervical cancer. Sociol Health Illn. 2008, 30: 886-99. 10.1111/j.1467-9566.2008.01100.x.PubMed
63.
Colgrove J, Abiola S, Mello MM: HPV vaccination mandates--lawmaking amid political and scientific controversy. N Engl J Med. 2010, 363: 785-91. 10.1056/NEJMsr1003547.PubMed
64.
Haber G, Malow RM, Zimet GD: The HPV vaccine mandate controversy. J Pediatr Adolesc Gynecol. 2007, 20: 325-31. 10.1016/j.jpag.2007.03.101.PubMed
65.
Aronowitz R: Gardasil: A Vaccine Against Cancer and a Drug to reduce risk. Three shots at prevention: The HPV vaccine and the politics of medicine's simple solutions. Edited by: Wailoo, K, Livingston J, Epstein S, Aronowitz R. 2010, Baltimore: Johns Hopkins University Press, 21-38. 1
66.
Hunt A, Connell E: The HPV vaccination campaign: A project of moral regulation in an era of biopolitics. Can J Sociol. 2010, 35: 1-63-82
67.
Phillips SP: Defining and measuring gender: A social determinant of health whose time has come. Int J Equity Health. 2005, 4: 11-10.1186/1475-9276-4-11.PubMedCentralPubMed
68.
Frazer I: Human Papillomaviruses. Vaccines: A biography. Edited by: Artenstein AW. 2010, New York: Springer
69.
Tjalma WA, Arbyn M, Paavonen J, van Waes TR, Bogers JJ: Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer. Int J Gynecol Cancer. 2004, 14: 751-61. 10.1111/j.1048-891X.2004.014505.x.PubMed
70.
Leggatt GR, Frazer IH: HPV vaccines: the beginning of the end for cervical cancer. Curr Opin Immunol. 2007, 19: 232-8. 10.1016/j.coi.2007.01.004.PubMed
71.
Zimet GD, Liddon N, Rosenthal SL, Lazcano-Ponce E, Allen B: Chapter 24: Psychosocial aspects of vaccine acceptability. Vaccine. 2006, 24 (Suppl 3): 201-9.
72.
Habel MA, Liddon N, Stryker JE: The HPV vaccine: a content analysis of online news stories. J Womens Health (Larchmt). 2009, 18: 401-7. 10.1089/jwh.2008.0920.
73.
Hughes J, Cates JR, Liddon N, Smith JS, Gottlieb SL, Brewer NT: Disparities in how parents are learning about the human papillomavirus vaccine. Cancer Epidemiol Biomarkers Prev. 2009, 18: 363-72. 10.1158/1055-9965.EPI-08-0418.PubMed
74.
Kelly BJ, Leader AE, Mittermaier DJ, Hornik RC, Cappella JN: The HPV vaccine and the media: how has the topic been covered and what are the effects on knowledge about the virus and cervical cancer?. Patient Educ Couns. 2009, 77: 308-13. 10.1016/j.pec.2009.03.018.PubMedCentralPubMed
75.
Forster A, Wardle J, Stephenson J, Waller J: Passport to promiscuity or lifesaver: press coverage of HPV vaccination and risky sexual behavior. J Health Commun. 2010, 15: 205-17. 10.1080/10810730903528066.PubMed
76.
Hilton S, Hunt K, Langan M, Bedford H, Petticrew M: Newsprint media representations of the introduction of the HPV vaccination programme for cervical cancer prevention in the UK (2005-2008). Soc Sci Med. 2010, 70: 942-50. 10.1016/j.socscimed.2009.11.027.PubMedCentralPubMed
77.
78.
Epstein S: The Great Undiscussable: HPV, Anal Cancer and Gay Men's Health. Three shots at prevention: The HPV va ccine and the politics of medicine's simple solutions. Edited by: Wailoo K, Livingston J, Epstein S, Aronowitz R. 2010, Baltimore: Johns Hopkins University Press, 61-90. 1
79.
Mayer KH, Bradford JB, Makadon HJ, Stall R, Goldhammer H, Landers S: Sexual and gender minority health: what we know and what needs to be done. Am J Public Health. 2008, 98: 989-95. 10.2105/AJPH.2007.127811.PubMedCentralPubMed
80.
Crosbie EJ, Brabin L: Cervical cancer: problem solved? Vaccinating girls against human papillomavirus. BJOG. 2010, 117: 137-42. 10.1111/j.1471-0528.2009.02369.x.PubMed
81.
Adams M, Jasani B, Fiander A: Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine. 2007, 25: 3007-13. 10.1016/j.vaccine.2007.01.016.PubMed
82.
Howlett RI, Miller AB, Pasut G, Mai V: Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination. Prev Med. 2009, 48: 432-7. 10.1016/j.ypmed.2008.12.022.PubMed
83.
Stanley M, Villa LL: Monitoring HPV vaccination. Vaccine. 2008, 26 (Suppl 1): A24-7.PubMed
84.
Bonanni P, Cohet C, Kjaer SK, Latham NB, Lambert PH, Reisinger K, Haupt RM: A summary of the post-licensure surveillance initiatives for Gardasil/Silgard. Vaccine. 2010, 28: 4719-30. 10.1016/j.vaccine.2010.04.070.PubMed
85.
Black AD, Car J, Pagliari C, Anandan C, Cresswell K, Bokun T, McKinstry B, Procter R, Majeed A, Sheikh A: The Impact of eHealth on the Quality and Safety of Health Care: A Systematic Overview. PLoS Med. 2011, 8: e1000387-10.1371/journal.pmed.1000387.PubMedCentralPubMed
86.
Heffernan ME, Garland SM, Kane MA: Global reduction of cervical cancer with human papillomavirus vaccines: insights from the hepatitis B virus vaccine experience. Sex Health. 2010, 7: 383-90. 10.1071/SH09134.PubMed
87.
Coates RA, Rankin JG: Cost without benefit? The introduction of hepatitis B vaccine in Canada. Can Med Assoc J. 1983, 128: 1158-60.PubMedCentralPubMed
88.
Kane MA: Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine. Gynecol Oncol. 2010, 117 (2): S32-5. 10.1016/j.ygyno.2010.01.029.PubMed
89.
Dickerson JB, Smith ML, Ory MG: Increasing uptake of Gardasil among American adolescents: Comparisons with the history of Hepatitis B vaccination. Hum Vaccin. 2011,
90.
Rothman SM, Rothman DJ: Marketing HPV vaccine: implications for adolescent health and medical professionalism. JAMA. 2009, 302: 781-6. 10.1001/jama.2009.1179.PubMed
91.
Livingston J, Epstein S, Aronowitz R: Vaccine Timelines. Three shots at prevention: The HPV vaccine and the politics of medicine's simple solutions. Edited by: Wailoo K, Livingston J, Epstein S, Aronowitz R. 2010, Baltimore: Johns Hopkins University Press, xix-xxx. 1
92.
Scheifele D: Universal childhood hepatitis B vaccination: infants vs. preadolescents, the Canadian perspective. Pediatr Infect Dis J. 1998, 17 (Suppl 7): S35-7.PubMed
93.
Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G: Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics. 2009, 27: 127-47. 10.2165/00019053-200927020-00004.PubMed
94.
Friedman AL, Shepeard H: Exploring the knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV: findings from CDC focus group research and implications for practice. Health Educ Behav. 2007, 34: 471-85.PubMed
95.
Lee PW, Kwan TT, Tam KF, Chan KK, Young PM, Lo SS, Cheung AN, Ngan HY: Beliefs about cervical cancer and human papillomavirus (HPV) and acceptability of HPV vaccination among Chinese women in Hong Kong. Prev Med. 2007, 45: 130-4. 10.1016/j.ypmed.2007.07.013.PubMed
96.
Rosenthal D, Dyson S, Pitts M, Garland S: Challenges to accepting a human papilloma virus (HPV) vaccine: a qualitative study of Australian women. Women Health. 2007, 45: 59-73. 10.1300/J013v45n02_04.PubMed
97.
Scarinci IC, Garcés-Palacio IC, Partridge EE: An examination of acceptability of HPV vaccination among African American women and Latina immigrants. J Womens Health (Larchmt). 2007, 16: 1224-33. 10.1089/jwh.2006.0175.
98.
Keating KM, Brewer NT, Gottlieb SL, Liddon N, Ludema C, Smith JS: Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer. J Adolesc Health. 2008, 43 (Suppl 4): S61-7.PubMed
99.
Kwan TT, Chan KK, Yip AM, Tam KF, Cheung AN, Young PM, Lee PW, Ngan HY: Barriers and facilitators to human papillomavirus vaccination among Chinese adolescent girls in Hong Kong: a qualitative-quantitative study. Sex Transm Infect. 2008, 84: 227-32. 10.1136/sti.2007.029363.PubMed
100.
Toffolon-Weiss M, Hagan K, Leston J, Peterson L, Provost E, Hennessy T: Alaska Native parental attitudes on cervical cancer, HPV and the HPV vaccine. Int J Circumpolar Health. 2008, 67: 363-73.PubMed
101.
Vanslyke JG, Baum J, Plaza V, Otero M, Wheeler C, Helitzer DL: HPV and cervical cancer testing and prevention: knowledge, beliefs, and attitudes among Hispanic women. Qual Health Res. 2008, 18: 584-96. 10.1177/1049732308315734.PubMed
102.
Bair RM, Mays RM, Sturm LA, Zimet GD: Acceptability of the human papillomavirus vaccine among Latina mothers. J Pediatr Adolesc Gynecol. 2008, 21: 329-34. 10.1016/j.jpag.2008.02.007.PubMed
103.
Bingham A, Drake JK, LaMontagne DS: Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Arch Pediatr Adolesc Med. 2009, 163: 455-61. 10.1001/archpediatrics.2009.50.PubMed
104.
Do H, Seng P, Talbot J, Acorda E, Coronado GD, Taylor VM: HPV vaccine knowledge and beliefs among Cambodian American parents and community leaders. Asian Pac J Cancer Prev. 2009, 10: 339-44.PubMedCentralPubMed
105.
Harries J, Moodley J, Barone MA, Mall S, Sinanovic E: Preparing for HPV vaccination in South Africa: key challenges and opinions. Vaccine. 2009, 27: 38-44. 10.1016/j.vaccine.2008.10.033.PubMed
106.
Katz ML, Reiter PL, Heaner S, Ruffin MT, Post DM, Paskett ED: Acceptance of the HPV vaccine among women, parents, community leaders, and healthcare providers in Ohio Appalachia. Vaccine. 2009, 27: 3945-52. 10.1016/j.vaccine.2009.04.040.PubMedCentralPubMed
107.
Madhivanan P, Krupp K, Yashodha MN, Marlow L, Klausner JD, Reingold AL: Attitudes toward HPV vaccination among parents of adolescent girls in Mysore, India. Vaccine. 2009, 27: 5203-8. 10.1016/j.vaccine.2009.06.073.PubMed
108.
Marlow LA, Wardle J, Waller J: Attitudes to HPV vaccination among ethnic minority mothers in the UK: an exploratory qualitative study. Hum Vaccin. 2009, 5: 105-10. 10.4161/hv.5.2.7368.PubMed
109.
Wong LP: HPV information needs, educational messages and channel of delivery preferences: views from developing country with multiethnic populations. Vaccine. 2009, 27: 1410-5. 10.1016/j.vaccine.2008.12.045.PubMed
110.
Krupp K, Marlow LA, Kielmann K, Doddaiah N, Mysore S, Reingold AL, Madhivanan P: Factors associated with intention-to-recommend human papillomavirus vaccination among physicians in Mysore, India. J Adolesc Health. 2010, 46: 379-84. 10.1016/j.jadohealth.2009.10.001.PubMed
111.
Kaler A: Health interventions and the persistence of rumour: the circulation of sterility stories in African public health campaigns. Soc Sci Med. 2009, 68: 1711-9. 10.1016/j.socscimed.2009.01.038.PubMed
112.
Dugas M, Dubé E, Kouyaté B, Sanou A, Bibeau G: Portrait of a lengthy vaccination trajectory in Burkina Faso: from cultural acceptance of vaccines to actual immunization. BMC Int Health Hum Rights. 2009, 9 (Suppl 1): S9-10.1186/1472-698X-9-S1-S9.PubMedCentralPubMed
113.
Sherris J, Friedman A, Wittet S, Davies P, Steben M, Saraiya M: Chapter 25: Education, training, and communication for HPV vaccines. Vaccine. 2006, 24 (Suppl 3): 210-8.
114.
115.
McCarthy C: Toward a Definition of Interiority. 2005, Space and Culture, 8: 112-125.
116.
Stanley M: Human papillomavirus vaccines versus cervical cancer screening. Clin Oncol (R Coll Radiol). 2008, 20: 388-94.
117.
Mackroth MS, Irwin K, Vandelaer J, Hombach J, Eckert LO: Immunizing school-age children and adolescents: experience from low- and middle-income countries. Vaccine. 2010, 28: 1138-47. 10.1016/j.vaccine.2009.11.008.PubMed
118.
Ogilvie GS, Remple VP, Marra F, McNeil SA, Naus M, Pielak KL, Ehlen TG, Dobson SR, Money DM, Patrick DM: Parental intention to have daughters receive the human papillomavirus vaccine. CMAJ. 2007, 177: 1506-12. 10.1503/cmaj.071022.PubMedCentralPubMed
119.
Watson M, Shaw D, Molchanoff L, McInnes C: Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. Aust N Z J Public Health. 2009, 33: 365-70. 10.1111/j.1753-6405.2009.00409.x.PubMed
120.
121.
Stöckl A: Public discourses and policy making: the HPV vaccination from the European perspective. Three shots at prevention: The HPV vaccine and the politics of medicine's simple solutions. Edited by: Wailoo K, Livingston J, Epstein S, Aronowitz R. 2010, Baltimore: Johns Hopkins University Press, 254-269. 1
122.
Humiston SG, Rosenthal SL: Challenges to vaccinating adolescents: vaccine implementation issues. Pediatr Infect Dis J. 2005, 24: S134-40. 10.1097/01.inf.0000166161.12087.94.PubMed
123.
Hernandez G, Nestor C: Educating teens about vaccines. J Pediatr Health Care. 2006, 20: 342-9. 10.1016/j.pedhc.2006.07.002.PubMed
124.
125.
126.
Lippman A, Melnychuk R, Shimmin C, Boscoe M: Human papillomavirus, vaccines and women's health: questions and cautions. CMAJ. 2007, 177: 484-7. 10.1503/cmaj.070944.PubMedCentralPubMed
127.
Haas M, Ashton T, Blum K, Christiansen T, Conis E, Crivelli L, Lim MK, Lisac M, Macadam M, Schlette S: Drugs, sex, money and power: an HPV vaccine case study. Health Policy. 2009, 92: 288-95. 10.1016/j.healthpol.2009.05.002.PubMed
128.
MacDonald N, Hébert PC: Human papillomavirus vaccine: waiting for a miracle. CMAJ. 2007, 177: 433-435. 10.1503/cmaj.071057.PubMedCentralPubMed
129.
Franco EL, Bosch FX, Cuzick J, Schiller JT, Garnett GP, Meheus A, Wright TC: Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine. 2006, 24: S3/242-9.
Metadata
Title
Global challenges of implementing human papillomavirus vaccines
Authors
Janice E Graham
Amrita Mishra
Publication date
01-12-2011
Publisher
BioMed Central
Published in
International Journal for Equity in Health / Issue 1/2011
Electronic ISSN: 1475-9276
DOI
https://doi.org/10.1186/1475-9276-10-27

Other articles of this Issue 1/2011

International Journal for Equity in Health 1/2011 Go to the issue

Research

A rapid equity focused health impact assessment of a policy implementation plan: An Australian case study and impact evaluation

Research

Challenges and opportunities for policy decisions to address health equity in developing health systems: case study of the policy processes in the Indian state of Orissa

Research

Who pays for health care in Ghana?

Research

Equity implications of coverage and use of insecticide treated nets distributed for free or with co-payment in two districts in Tanzania: A cross-sectional comparative household survey

Research

Health equity in the New Zealand health care system: a national survey

Research

Does socioeconomic status affect the association of social relationships and health? A moderator analysis